Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 7Bevacizumab 4sargramostim 2rindopepimut 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 21-methyltryptophan 2ridaforolimus 1prinomastat 1pembrolizumab 1pamiparib 1marizomib 1interferon gamma-1b 1enzastaurin 1depatuxizumab mafodotin 1capmatinib 1Sucrose 1Spermine Synthase 1Radiosurgery 1Procarbazine 1ONC206 1NVP-BKM120 1Leflunomide 1Interferon-gamma 1Interferon-beta 1Immunotherapy 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gliosarcoma × Sucrose × Clear all
NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Epitopoietic Research Corporation

Phase 2 Active not recruiting
84 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡